Lilly shares are trading higher after the company's Alzheimer's drug donanemab received a unanimous 11-0 vote from the FDA's Peripheral and Central Nervous System Drugs Advisory Committee.
Portfolio Pulse from Benzinga Newsdesk
Lilly shares are trading higher after the company's Alzheimer's drug donanemab received a unanimous 11-0 vote from the FDA's Peripheral and Central Nervous System Drugs Advisory Committee.
June 11, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lilly's Alzheimer's drug donanemab received a unanimous 11-0 vote from the FDA's Peripheral and Central Nervous System Drugs Advisory Committee, leading to a rise in the company's shares.
The unanimous vote from the FDA advisory committee is a strong positive signal for the approval of Lilly's Alzheimer's drug donanemab. This increases investor confidence and is likely to drive the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100